Based on the initial results of the BOLOERO-3 trial, it appears that such combination represents a promising therapeutic strategy to target patients with advanced ERBB2+ breast cancer developing resistance to conventional therapy (Andre et al. 2014). The gene discussed is ERBB2; the disease is breast cancer.